Type I Thyroplasty Is Safe in Patients Undergoing Antithrombotic Therapy

Introduction: Type I thyroplasty is one of the most useful surgeries for unilateral vocal fold paralysis. The study objective was to determine whether type I thyroplasty is safe and perioperative antithrombotic management is acceptable in patients undergoing antithrombotic therapy. Methods: This is a single-hospital retrospective cohort study. The records of 204 patients who underwent type I thyroplasty at a Japanese university hospital, between 2008 and July 2018 were reviewed. We compared the prothrombin time international normalized ratio, prothrombin time, operative time, intraoperative blood loss, and intra- and postoperative complications between patients who did and did not receive antithrombotic therapy. Results: Of 204 patients, 51 (25%) received antithrombotic therapy (antithrombotic group). The remaining 153 patients were assigned to the control group. There were no significant differences in operative time, intraoperative blood loss, or intraoperative complications between the two groups. Sixteen (31%) patients in the antithrombotic group had a hemorrhage or hematoma in the vocal fold mucosa postoperatively, no patient had airway obstruction necessitating tracheostomy, and all patients recovered with follow-up observation only. There were no cases of intraoperative or postoperative complications, such as ischemic heart disease, ischemic stroke, or deep vein thrombosis. Conclusion: Type I thyroplasty with careful pre- and postoperative management is safe in patients undergoing antithrombotic therapy.

[1]  M. Yasaka,et al.  Management of Antithrombotic Agents During Surgery or Other Kinds of Medical Procedures With Bleeding: The MARK Study , 2020, Journal of the American Heart Association.

[2]  R. Sataloff,et al.  Incidence of and Risk Factors Associated With Vocal Fold Hemorrhage Following Type I Thyroplasty With Gore-Tex Implant. , 2020, Journal of voice : official journal of the Voice Foundation.

[3]  R. Sataloff,et al.  Prevalence and Long-term Consequences of Vocal Fold Hemorrhage in Patients who Underwent Microscopic Laryngeal Surgery or Type I Thyroplasty. , 2019, Journal of voice : official journal of the Voice Foundation.

[4]  S. Khariwala,et al.  When should therapeutic anticoagulation be restarted following major head and neck surgery? , 2018, The Laryngoscope.

[5]  J. Ioannidis.  The Proposal to Lower P Value Thresholds to .005. , 2018, JAMA.

[6]  C. Kunte,et al.  Prospective multicentre cohort study on 9154 surgical procedures to assess the risk of postoperative bleeding – a DESSI study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  David F. Schneider,et al.  Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures , 2016, Annals of Surgical Oncology.

[8]  W. Abuzeid,et al.  Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures , 2015, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[9]  T. Umezaki.  Tips and Pitfalls of Type I Thyroplasty , 2011 .

[10]  M. Gonen,et al.  Complications of Type I Thyroplasty and Arytenoid Adduction , 2001, The Laryngoscope.

[11]  N Isshiki,et al.  Progress in Laryngeal Framework Surgery , 2000, Acta oto-laryngologica.

[12]  W. Montgomery,et al.  Montgomery thyroplasty implant system. , 1997, The Annals of otology, rhinology & laryngology. Supplement.

[13]  N. Maragos,et al.  Airway Compromise in Thyroplasty Surgery , 2000, The Laryngoscope.

[14]  N. Isshiki,et al.  Thyroplasty type I (lateral compression) for dysphonia due to vocal cord paralysis or atrophy. , 1975, Acta oto-laryngologica.